ELORAC, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.eloracpharma.com
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Phase 3
Terminated
- Conditions
- Mycosis FungoidesSézary SyndromeLymphoma, T-Cell, Cutaneous
- Interventions
- Drug: Placebo Lotion
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02811783
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
🇺🇸Stony Brook Dermatology, Stony Brook, New York, United States
Finasteride Treatment of Severe Nodulocystic Acne
Phase 2
Completed
- Conditions
- NODULOCYSTIC ACNE
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT02502669
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Advanced Medcial Research Institiute, Miami Lakes, Florida, United States
🇺🇸Marietta Dermatology Clinical Research, Inc., Marietta, Georgia, United States
Evaluate the Effect of Elimune Capsules
Phase 1
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Dietary Supplement: Elimune Capsules
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02251678
- Locations
- 🇺🇸
NMFF Dermatology Clinic, Chicago, Illinois, United States
🇺🇸NM Lake Forest Hospital/ Women's Center, Lake Forest, Illinois, United States
🇺🇸University Hospitals Case Medical Center / Dept of Dermatology, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath